Last reviewed · How we verify
NCT06123416
Emotion Regulation and Cancer Caregiving
trial testing Expressive Writing in Breast Cancer in 30 participants. Completed in 15 July 2019.
15 July 2019
Quick facts
| Lead sponsor | Stanford University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 16 January 2019 |
| Primary completion | 15 July 2019 |
| Estimated completion | 15 July 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Expressive Writing
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Cancer — all drugs for Cancer →
- Healthy — all drugs for Healthy →
- Emotions — all drugs for Emotions →
Sponsor
Stanford University
Who can join
21 and older, any sex, with Breast Cancer or Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the study is to determine how the behaviors of cancer caregivers can impact patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Using expressive writing to improve cancer caregiver and patient health: A randomized controlled feasibility trial.
Eldesouky L, Gross JJ. · · 2024 · cited 3× · PMID 38522170 · DOI 10.1016/j.ejon.2024.102578
Verify or expand the search:
- PubMed search for NCT06123416
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Expressive Writing
Trials testing the same drug.
- NCT07298980 — ExBRAC- Expressive Writing in Breast Cancer · NA · not yet recruiting
- NCT05694832 — Expressive Writing in GVHD · EARLY_PHASE1 · terminated
- NCT05456100 — Chinese American Cancer Survivors Writing Study · NA · recruiting
- NCT05192434 — Trauma Intervention to Optimize PrEP Among Women Who Inject Drugs · NA · active not recruiting
- NCT04075773 — Brief Religious Alcohol Intervention · NA · completed
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Stanford University trials
Trials by the same sponsor.
- NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
- NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
- NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
- NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
- NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06123416 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stanford University
- Last refreshed: 13 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06123416.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing